生长激素治疗小于胎龄儿的研究进展  

Research progress of growth hormone in the treatment of small for gestational age infants

作　　者：林坤鸿 陈迪嘉 邢燕[1] 王新利[1] LIN Kunhong;CHEN Dijia;XING Yan;WANG Xinli(Department of Pediatrics,Peking University Third Hospital,Beijing 100191,China;Peking University Health Science Center)

机构地区：[1]北京大学第三医院儿科,北京100191 [2]北京大学医学部

出　　处：《中国儿童保健杂志》2024年第4期419-423,共5页Chinese Journal of Child Health Care

基　　金：国家重点研发计划(2021YFC2700700);北京大学第三医院小于胎龄儿生长发育队列(BYSYDL2022008);中华国际医学交流基金会中国儿童生长发育学术交流专项基金(Z-2019-41-2101-01);2020年度澳优-佳贝艾特科研基金(RS2020-23);北京大学第三医院青年孵育基金(BYSYFY2021014)。

摘　　要：通常情况下小于胎龄(SGA)儿在出生之后会发生追赶生长,但有部分SGA儿未能表现出足够的追赶生长,导致体格生长落后,并且成年后代谢性疾病风险增加。应用外源性生长激素替代治疗可保证和促进SGA儿追赶生长的发生,但随着生长激素在相关临床疾病发挥疗效的同时,生长激素是否可能带来长期风险亦逐步被临床关注,本文拟对生长激素治疗SGA的疗效和可能风险进行综述。Generally,small for gestational age(SGA)infants will catch up with growth after birth,but some SGAs fail to show enough catch-up growth,leading to physical growth backwardness,and the risk of metabolic diseases in adult offspring increases.The application of exogenous growth hormone replacement therapy can ensure and promote the occurrence of SGA catching up with growth.However,as growth hormone exerts therapeutic effects in related clinical diseases,clinical attention is gradually being paid to whether growth hormone may bring long-term risks.This article aims to review the efficacy and potential risks of growth hormone treatment for SGA.

关 键 词：小于胎龄儿 追赶生长 生长激素 

分 类 号：R72[医药卫生—儿科]